Microbials for the production of monoclonal antibodies and antibody fragments

Oliver Spadiut, Simona Capone, Florian Krainer, Anton Glieder, Christoph Herwig*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Monoclonal antibodies (mAbs) and antibody fragments represent the most important biopharmaceutical products today. Because full length antibodies are glycosylated, mammalian cells, which allow human-like N-glycosylation, are currently used for their production. However, mammalian cells have several drawbacks when it comes to bioprocessing and scale-up, resulting in long processing times and elevated costs. By contrast, antibody fragments, that are not glycosylated but still exhibit antigen binding properties, can be produced in microbial organisms, which are easy to manipulate and cultivate. In this review, we summarize recent advances in the expression systems, strain engineering, and production processes for the three main microbials used in antibody and antibody fragment production, namely Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli.
Original languageEnglish
Pages (from-to)54-60
JournalTrends in Biotechnology
Volume32
Issue number1
DOIs
Publication statusPublished - 2014

Fields of Expertise

  • Human- & Biotechnology

Treatment code (Nähere Zuordnung)

  • Review

Fingerprint

Dive into the research topics of 'Microbials for the production of monoclonal antibodies and antibody fragments'. Together they form a unique fingerprint.

Cite this